Pharmaceutical compositions of goserelin sustained release microspheres

Inactive Publication Date: 2016-01-28
SHANDONG LUYE PHARMA CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0034]wherein, D90, D50 and D10 refer to the particle sizes respectively corresponding to 90%, 50% and 10% of the cumulative distri

Problems solved by technology

When it is administrated with a non-physiological pulse frequency for a long period of time and at a large dose, it can inhibit the hypophysis from secreting luteinizing hormone (LH) and follicle stimulating hormone (FSH), resulting in a decrease in the hormone secretion capacity of gonad and the atrophy of sexual organs.
However, studies have shown that when microspheres are

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions of goserelin sustained release microspheres
  • Pharmaceutical compositions of goserelin sustained release microspheres
  • Pharmaceutical compositions of goserelin sustained release microspheres

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0040]Appropriate amount of goserelin acetate and Poloxamer 188 were weighed and ball-mill mixed at frequency of 15 Hz for 5 min so as to obtain a mixture of solid powder. 430 mg mixture of goserelin and Poloxamer 188 (the measured amount of goserelin was 215 mg) was accurately weighed for later use. 1.721 g of PLGA (75 / 25, 0.35, 42,000) was weighed and dissolved in 10 ml of dichloromethane to form an oil phase; and then the pretreated drug mixture of solid powder was added into the oil phase, and subjected to emulsification in a high shear emulsifier (6,500 rpm, 3 min) so as to obtain a s / o primary emulsion. The primary emulsion was added into 1,000 ml of a 0.5% PVA solution at 6° C. under homogenization at 1,800 rpm, and then it was homogeneously emulsified for 2 min to obtain an S / O / W double emulsion. The double emulsion was stirred to volatilize and remove the organic solvent; the residue was washed and freeze-dried to obtain powdery microspheres. The microspheres had a drug loa...

example 2

[0041]The melting temperature of a melt extruder was set at 80° C. Appropriate amount of goserelin acetate and Poloxamer 407 were sifted and mixed. The mixture was fed into the cavity of the extruder. The stirring speed was set to n=60 and the stirring mixing time to 3 min. Then the valve handle was released to extrude the melted material, which was then allowed to become cool naturally. The material was ball-mill smashed for 2 min. 316 mg of the mixture of goserelin and Poloxamer 188 (the measured amount of goserelin was 158 mg) was accurately weighed for later use, 1.672 g of PLGA (25 / 75, 0.24, 25,000) was weighed and dissolved in 10 ml of dichloromethane to form an oil phase; and then the pretreated drug mixture of solid powder was added into the oil phase, and subjected to emulsification in a high shear emulsifier (6,500 rpm, 3 min) so as to obtain a s / o primary emulsion. The primary emulsion was added into 1,000 ml of a 0.5% PVA solution at 6° C. under homogenization at 1,800 r...

example 3

[0042]Appropriate amount of goserelin acetate and Poloxamer 188 were weighed and dissolved in water to form a clear solution, and then the solution was sprayed dried so as to obtain a mixture of solid powder. 47 mg spray-dried mixture of goserelin and Poloxamer 188 (the measured amount of goscrelin was 23 mg) was accurately weighed and put into a vial. 1.951 g of PLGA (65 / 35, 0.29, 32,000) was weighed and dissolved in 10 ml of dichloromethane to form an oil phase; and then the pretreated drug mixture of solid powder was added into the oil phase, and subjected to emulsification in a high shear emulsifier (6,500 rpm, 3 min) so as to obtain a s / o primary emulsion. The primary emulsion was added into 1,000 ml of a 0.5% PVA solution at 6° C. under homogenization at 1,800 rpm, and then it was homogeneously emulsified for 2 min to obtain an S / O / W double emulsion. The double emulsion was stirred to volatilize and remove the organic solvent; the residue was washed and freeze-dried to obtain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly(lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The application is a continuation application of International Application No. PCT / CN2014 / 075441, filed Apr. 16, 2014, which claims priority to Chinese Application No. 201310136505.6, filed Apr. 18, 2013, the contents of each of which are incorporated by reference in their entireties for all purposes.FIELD OF THE INVENTION[0002]The present disclosure relates to pharmaceutical preparations and, more particularly, to compositions of long-acting sustained release goserelin microspheres, methods for preparing the same and use of the same.BACKGROUND OF THE INVENTION[0003]Gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH), is a hormone closely related to reproductive functions. When an exogenous LHRH or an analogue thereof is administrated with a physiological pulse frequency (once per 90 min) for a short period of time and at a small dose, it produces some promoting effects to the pituitary-gonada...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/16A61K38/09
CPCA61K9/1647A61K9/1682A61K38/09A61K9/1641A61K9/1694A61P5/00A61P5/06A61P13/00A61P13/08A61P15/00A61P15/08A61P35/00A61K47/34
Inventor SUN, WEIZHANG, XUEMEIWANG, TAOLENG, GUANGYISUN, KAOXIANGLI, YOUXINLIU, WANHUI
Owner SHANDONG LUYE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap